| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | — |
| R&D Expense | $5.8M | +73.1% | +15.0% |
| SG&A Expense | $7.5M | +17.3% | +113.2% |
| Operating Income | -$13.4M | -36.5% | -55.4% |
| Net Income | -$11.8M | -32.0% | -60.9% |
| EPS (Basic) | -$0.26 | -18.2% | +21.2% |
| EPS (Diluted) | -$0.26 | -18.2% | +21.2% |
| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $188.8M | +99.8% | +141.2% |
| Accounts Receivable | $130K | +1757.1% | +6400.0% |
| Current Assets | $189.6M | +99.4% | +140.9% |
| Total Assets | $190.7M | +98.6% | +141.2% |
| Current Liabilities | $2.8M | +38.3% | -9.3% |
| Total Liabilities | $3.3M |
| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$7.1M | -112.7% | — |
| Capital Expenditures | $11K | — | — |
| Investing Cash Flow | -$11K | — | — |
| Financing Cash Flow | $98.2M | — | — |
| Free Cash Flow | -$7.1M | — | — |
| +6.2% |
| Stockholders' Equity | $187.4M | +100.2% | +146.7% |